8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Feb 26, 2026·SEC
Nuvalent, Inc.(NUVL)Earnings, Financials & Key Ratios
NUVL•NASDAQ
Price updated Jun 19, 2026
AboutNuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA$0
- Net Income-$425M-63.1%
- EPS (Diluted)-5.85-48.9%
- ROE-36.7%-24.6%
NUVL Key Insights
Nuvalent, Inc. (NUVL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 81 (top 19%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 96.4% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NUVL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NUVL Price & Volume
Nuvalent, Inc. (NUVL) stock price & volume — 10-year historical chart
Loading chart...
NUVL Growth Metrics
Nuvalent, Inc. (NUVL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-49.6%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-38.04%
Return on Capital
10 Years-132.04%
5 Years-29.18%
3 Years-30.48%
Last Year-34.39%
NUVL Recent Earnings
Nuvalent, Inc. (NUVL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.39-3.0%
$1.35
Rev
—
$486,000
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$1.29+12.8%
$1.48
Rev
—
$7M
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$1.70-22.3%
$1.39
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.31-3.1%
$1.27
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.39vs $1.35-3.0% | —vs $486,000 |
| Q1 2026 | Feb 26, 2026 | $1.29vs $1.48+12.8% | —vs $7M |
| Q4 2025 | Oct 30, 2025 | $1.70vs $1.39-22.3% | — |
| Q3 2025 | Aug 7, 2025 | $1.31vs $1.27-3.1% | — |
Based on last 12 quarters of dataView full earnings history →
NUVL Peer Comparison
Nuvalent, Inc. (NUVL) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KROS | 340.78M | 10.65 | 4.63 | 67.75% | -256.6% | -17.04% | 0.06 | |
 TPST | 5.46M | 1.23 | -0.19 | -7.3% | 1.22 | |||
 MRUS | 6.83B | 90.00 | -26.87 | -12.38% | -6.54% | -50.62% | 0.02 | |
 ERAS | 4.25B | 13.67 | -31.07 | -77.01% | 0.14 | |||
 TARS | 2.72B | 63.16 | -39.72 | 146.71% | -9.02% | -14.19% | 0.27 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 |
Compare NUVL vs Peers
Nuvalent, Inc. (NUVL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NUVL Income Statement
Nuvalent, Inc. (NUVL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - | - |
Operating Expenses | 10.36M | 16.91M | 45.82M | 86.11M | 149.49M | 280.37M | 414.31M | 438.9M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 612K | 1.5M | 10.26M | 22.38M | 36.25M | 62.59M | 107.34M | 122.74M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 9.75M | 15.4M | 35.56M | 63.73M | 113.24M | 217.77M | 306.97M | 316.16M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -10.36M▲ 0% | -16.91M▼ 63.2% | -45.82M▼ 171.0% | -86.11M▼ 87.9% | -149.49M▼ 73.6% | -280.37M▼ 87.5% | -414.31M▼ 47.8% | -438.9M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -63.21% | -171.03% | -87.94% | -73.61% | -87.55% | -47.77% | - |
EBITDA | 0 | -16.91M | -45.82M | -86.11M | -126.22M | 0 | 0 | -346.28M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | -171.03% | -87.94% | -46.58% | 100% | - | -7.34% |
D&A (Non-Cash Add-back) | 10.36M | 0 | 0 | 0 | 0 | 280.37M | 414.31M | 102.23M |
EBIT | -11.81M | -16.91M | -45.82M | -86.11M | -126.22M | -280.37M | -424.79M | -464.84M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 38.32M | 44.73M | 29.23M |
Interest Income | 0 | 0 | 0 | 0 | 23.27M | 38.32M | 44.73M | 42.09M |
Interest Expense | 0 | 0 | 0 | 0 | 23.27M | 0 | 0 | 12.87M |
Other Income/Expense | -1.45M | 2.35M | -521K | 4.25M | 23.27M | 20.38M | -10.48M | -10.58M |
Pretax Income | -11.81M▲ 0% | -14.56M▼ 23.3% | -46.34M▼ 218.3% | -81.85M▼ 76.6% | -126.22M▼ 54.2% | -259.99M▼ 106.0% | -424.79M▼ 63.4% | -449.48M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 764K | 585K | 596K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -0.29% | -0.14% | -0.13% |
Net Income | -11.81M▲ 0% | -14.56M▼ 23.3% | -46.34M▼ 218.3% | -81.85M▼ 76.6% | -126.22M▼ 54.2% | -260.76M▼ 106.6% | -425.38M▼ 63.1% | -450.07M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -23.26% | -218.34% | -76.65% | -54.2% | -106.59% | -63.13% | -49.6% |
Net Income (Continuing) | -11.81M | -14.56M | -46.34M | -81.85M | -126.22M | -260.76M | -425.38M | -450.07M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.24▲ 0% | -0.64▼ 166.7% | -2.13▼ 232.8% | -1.65▲ 22.5% | -2.17▼ 31.5% | -3.93▼ 81.1% | -5.85▼ 48.9% | -5.72▲ 0% |
EPS Growth % | - | -166.67% | -232.81% | 22.54% | -31.52% | -81.11% | -48.85% | -38.04% |
EPS (Basic) | -0.24 | -0.64 | -2.13 | -1.65 | -2.17 | -3.93 | -5.85 | - |
Diluted Shares Outstanding | 48.28M | 22.86M | 21.78M | 49.67M | 58.22M | 66.41M | 72.69M | 78.67M |
Basic Shares Outstanding | 48.28M | 22.86M | 21.78M | 49.67M | 58.22M | 66.41M | 72.69M | 78.67M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
NUVL Balance Sheet
Nuvalent, Inc. (NUVL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3.32M | 10.65M | 290.63M | 477.99M | 726.49M | 1.13B | 1.39B | 1.31B |
Cash & Short-Term Investments | 3.02M | 10.33M | 288.11M | 472.16M | 719.9M | 1.12B | 1.37B | 1.29B |
Cash Only | 3.02M | 10.33M | 68.53M | 241.81M | 335.39M | 145.69M | 261.75M | 159.73M |
Short-Term Investments | 0 | 0 | 219.59M | 230.36M | 384.52M | 972.61M | 1.11B | 1.13B |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 314K | 0 | 5.83M | 6.58M | 14.15M | 0 | 20.46M |
Total Non-Current Assets | 0 | 0 | 3.2M | 4.47M | 5.9M | 9.3M | 20.28M | 23.21M |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 3.2M | 4.47M | 5.9M | 9.3M | 20.28M | 23.21M |
Total Assets | 3.32M▲ 0% | 10.65M▲ 221.0% | 293.82M▲ 2659.9% | 482.46M▲ 64.2% | 732.38M▲ 51.8% | 1.14B▲ 55.9% | 1.41B▲ 23.7% | 1.33B▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 221.05% | 2659.95% | 64.2% | 51.8% | 55.9% | 23.73% | 80.64% |
Total Current Liabilities | 4.35M | 4.38M | 8.79M | 19.48M | 31.82M | 54.02M | 91.17M | 81.05M |
Accounts Payable | 723K | 1.25M | 2.89M | 7.2M | 9.27M | 5.22M | 30.16M | 22.14M |
Days Payables Outstanding | - | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | -3.15M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6.46M | 2.59M | 3.16M | 7.43M | 7.33M | 0 | 0 | 58.91M |
Current Ratio | 0.76x | 2.43x | 33.07x | 24.54x | 22.83x | 20.96x | 15.27x | 16.14x |
Quick Ratio | 0.76x | 2.43x | 33.07x | 24.54x | 22.83x | 20.96x | 15.27x | 16.14x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 16.22M | 37.59M | 0 | 0 | 0 | 17.94M | 73.19M | 75.73M |
Long-Term Debt | 2.17M | 2.23M | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 14.05M | 35.35M | 0 | 0 | 0 | 17.94M | 73.19M | 75.73M |
Total Liabilities | 20.57M | 41.97M | 8.79M | 19.48M | 31.82M | 71.96M | 164.37M | 156.78M |
Total Debt | 2.17M | 2.23M | 0 | 0 | 0 | 0 | 0 | 0 |
Net Debt | -843K | -8.1M | -68.53M | -241.81M | -335.39M | -145.69M | -261.75M | -159.73M |
Debt / Equity | - | - | - | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.46x |
Interest Coverage | - | - | - | - | -5.42x | - | - | -36.13x |
Total Equity | -17.26M▲ 0% | -31.32M▼ 81.5% | 285.04M▲ 1010.0% | 462.98M▲ 62.4% | 700.56M▲ 51.3% | 1.07B▲ 52.7% | 1.25B▲ 16.7% | 1.17B▲ 0% |
Equity Growth % | - | -81.52% | 1009.99% | 62.43% | 51.32% | 52.7% | 16.69% | 55.77% |
Book Value per Share | -0.36 | -1.37 | 13.08 | 9.32 | 12.03 | 16.11 | 17.17 | 14.93 |
Total Shareholders' Equity | -17.26M | -31.32M | 285.04M | 462.98M | 700.56M | 1.07B | 1.25B | 1.17B |
Common Stock | 0 | 0 | 5K | 6K | 7K | 8K | 8K | 8K |
Retained Earnings | -17.33M | -31.89M | -78.22M | -160.08M | -286.3M | -547.05M | -972.43M | -1.08B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -14.05M | -280K | -228K | -494K | 31K | -59K | 2.35M | -1.35M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NUVL Cash Flow Statement
Nuvalent, Inc. (NUVL) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.64M | -14.95M | -40M | -64.97M | -99.74M | -185.06M | -275.21M | -312.79M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -55.09% | -167.58% | -62.43% | -53.51% | -85.55% | -48.71% | -226.71% |
Net Income | -11.81M | -14.56M | -46.34M | -81.85M | -126.22M | -260.76M | -425.38M | -450.07M |
Depreciation & Amortization | 0 | 0 | 215K | -373K | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 41K | 729K | 3.55M | 10.32M | 25.56M | 60.58M | 0 | 22.07M |
Deferred Taxes | 0 | 0 | -215K | -5.74M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.57M | -2.39M | 846K | 5.74M | -10.11M | 3.27M | 130.96M | 121.07M |
Working Capital Changes | 562K | 1.27M | 1.94M | 6.93M | 11.03M | 11.84M | 19.21M | -5.85M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 424K | 529K | 1.64M | 4.21M | 2.17M | -4.05M | 24.6M | -4.03M |
Cash from Investing | 0 | 0 | -220.03M | -10.66M | -143.53M | -573.51M | -124.08M | -168.91M |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 0 | 22.27M | 318.22M | 248.92M | 336.85M | 568.88M | 515.34M | 520.59M |
Debt Issued (Net) | 0 | -250K | 284K | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 22.5M | 321.92M | 248.63M | 324.3M | 569.99M | 515.34M | 520.59M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 15K | -3.98M | 286K | 12.55M | -1.1M | 0 | 0 |
Net Change in Cash | -9.64M▲ 0% | 7.32M▲ 175.9% | 58.19M▲ 695.4% | 173.28M▲ 197.8% | 93.58M▼ 46.0% | -189.7M▼ 302.7% | 116.05M▲ 161.2% | 38.9M▲ 0% |
Free Cash Flow | -9.64M▲ 0% | -14.95M▼ 55.1% | -40M▼ 167.6% | -64.97M▼ 62.4% | -99.74M▼ 53.5% | -185.06M▼ 85.5% | -275.21M▼ 48.7% | -312.79M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | -55.09% | -167.58% | -62.43% | -53.51% | -85.55% | -48.71% | -53.48% |
FCF per Share | -0.20 | -0.65 | -1.84 | -1.31 | -1.71 | -2.79 | -3.79 | -3.98 |
FCF Conversion (FCF/Net Income) | 0.82x | 1.03x | 0.86x | 0.79x | 0.79x | 0.71x | 0.65x | 0.69x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NUVL Key Ratios
Nuvalent, Inc. (NUVL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -36.53% | -21.89% | -21.7% | -29.46% | -36.7% | -42.78% |
Return on Invested Capital (ROIC) | - | -38.81% | -29.51% | -38.24% | -32.62% | -32.53% | -37.16% |
Debt / Equity | - | - | - | - | - | - | 0.00x |
Interest Coverage | - | - | - | -5.42x | - | - | -36.13x |
FCF Conversion | 1.03x | 0.86x | 0.79x | 0.79x | 0.71x | 0.65x | 0.69x |
Related:NUVL Dividend History·NUVL Revenue History·NUVL Price History·NUVL P/E History·NUVL Financial Ratios·NUVL Institutional Holders
NUVL SEC Filings & Documents
Nuvalent, Inc. (NUVL) SEC filings — annual & quarterly reports (10-K, 10-Q)
NUVL Frequently Asked Questions
Nuvalent, Inc. (NUVL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nuvalent, Inc. (NUVL) grew revenue by 0.0% over the past year. Growth has been modest.
Nuvalent, Inc. (NUVL) reported a net loss of $450.1M for fiscal year 2025.
Dividend & Returns
Nuvalent, Inc. (NUVL) has a return on equity (ROE) of -36.7%. Negative ROE indicates the company is unprofitable.
Nuvalent, Inc. (NUVL) had negative free cash flow of $312.8M in fiscal year 2025, likely due to heavy capital investments.